LUNDBECK CUTS 2006 TARGET DUE TO SLOWER US SALES

Danish pharmaceutical group Lundbeck on Tuesday cut its 2006 financial targets due slower sales of its antidepressant drug Lexapro by its U.S. partner Forest Labs. Lundbeck said Forest Labs had decided to cut its inventories of the drug as a consequence of the slower market.
Reuters